Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

July’s top stories: Merck CMV Phase III trial, Sanofi vaccine study results

Merck enrolled the first patient in its global Phase III clinical trial of letermovir for the prevention of cytomegalovirus infection in high-risk bone marrow transplant patients, while Sanofi Pasteur reported positive results from its Phase III dengue vaccine efficacy trial carried out in five countries in Asia. DrugDevelopment-technology.com wraps-up the key headlines from July 2014.

Go Top